Clinical Trial Update: Compassionate Use Protocol for the Treatment of Autoinflammatory Syndromes

View source ↗

Summary

The update notes that Eli Lilly's baricitinib has been approved for marketing for autoinflammatory syndromes including CANDLE, Juvenile Dermatomyositis, SAVI, a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aicardi-goutières Syndrome
• Atypical Neutrophilic Dermatosis with Lipodystrophy and Elevated Temperature
• Juvenile Dermatomyositis
• Sting-associated Vasopathy with Onset in Infancy

Drugs mentioned

• Baricitinib (baricitinib)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Chronic Atypical Neutrophilic Dermatosis With Lipodystrophy and Elevated Temperature (CANDLE), Juvenile Dermatomyositis (JDM) | Status: APPROVED_FOR_MARKETING